Puma Biotechnology | PBYI - Cash And Equivalent


Puma Biotechnology reported $53.52M in Cash and Equivalent for its fiscal quarter ending in September of 2025.





Cash And Equivalent Change Date
Agios Pharmaceuticals USD 99.65M 13.95M Jun/2026
Alnylam Pharmaceuticals USD 1.71B 2.46M Jun/2026
Amgen USD 13.99B 1.95B Jun/2026
Biogen USD 1.28B 2.1B Jun/2026
BioMarin Pharmaceutical USD 874M 1.35B Jun/2026
Daiichi Sankyo JPY 449.81B 92.35B Mar/2026
Exelixis USD 281.45M 55.3M Jun/2026
Gilead Sciences USD 7.63B 64M Mar/2026
Glaxosmithkline GBP 3.44B 146M Mar/2026
Incyte USD 3.98B 33.45M Jun/2026
MacroGenics USD 113.91M 47.39M Jun/2026
Moderna USD 1.72B 185M Jun/2026
Novartis USD 7.62B 739M Jun/2026
Pfizer USD 976M 727M Jun/2026
PTC Therapeutics USD 1.05B 215.9M Jun/2026
Puma Biotechnology USD 53.52M 1.14M Sep/2025
Regeneron Pharmaceuticals USD 2.46B 506.8M Jun/2026
Roche Holding CHF 7.55B 579M Jun/2025
Sangamo BioSciences USD 38.34M 13.16M Jun/2025
Sarepta Therapeutics USD 571.15M 106.7M Jun/2026
Takeda JPY 460.98B 134.07B Jun/2026
TG Therapeutics USD 612.25M 170.04M Jun/2026
Ultragenyx Pharmaceutical USD 125M 50M Jun/2026
Vanda Pharmaceuticals USD 84.85M 14.83M Dec/2025
Vertex Pharmaceuticals USD 7.85B 605.7M Jun/2026